Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). 2 PR and 8 SD among 18 patients with KRAS Mutant NSCLC.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/997
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 1
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Does Not Support
- Drug
- MEK Inhibitor RO4987655
- Evidence Level
- B
- Clinical Significance
- N/A
- Pubmed
- 24947927
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| MEK Inhibitor RO4987655 | N/A | false |